Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Veenstra-VanderWeele J, Blakely RD.

Neuropsychopharmacology. 2012 Jan;37(1):196-212. doi: 10.1038/npp.2011.185. Epub 2011 Sep 21. Review.

2.

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.

Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V.

Curr Alzheimer Res. 2011 Dec;8(8):808-17. Review.

PMID:
21592055
3.

Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary.

Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders.

Washington (DC): National Academies Press (US); 2008.

4.

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S21-9. doi: 10.1016/S0305-7372(10)70016-5. Review.

PMID:
21129606
5.

Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Krueger DD, Bear MF.

Annu Rev Med. 2011;62:411-29. doi: 10.1146/annurev-med-061109-134644. Review.

6.

Rethinking schizophrenia.

Insel TR.

Nature. 2010 Nov 11;468(7321):187-93. doi: 10.1038/nature09552.

PMID:
21068826
7.

What's next after 50 years of psychiatric drug development: an FDA perspective.

Laughren TP.

J Clin Psychiatry. 2010 Sep;71(9):1196-204. doi: 10.4088/JCP.10m06262gry.

PMID:
20923624
8.

The clinical-basic interface in defining pathogenesis in disorders of neurodevelopmental origin.

Thompson BL, Levitt P.

Neuron. 2010 Sep 9;67(5):702-12. doi: 10.1016/j.neuron.2010.08.037.

9.

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS.

Science. 2010 Aug 20;329(5994):959-64. doi: 10.1126/science.1190287.

10.

Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery.

Rowntree RK, McNeish JD.

Regen Med. 2010 Jul;5(4):557-68. doi: 10.2217/rme.10.36.

PMID:
20632859
11.

Integrating molecular diagnostics into anticancer drug discovery.

Peták I, Schwab R, Orfi L, Kopper L, Kéri G.

Nat Rev Drug Discov. 2010 Jul;9(7):523-35. doi: 10.1038/nrd3135. Epub 2010 Jun 7. Review.

PMID:
20531274
12.

Ethics in child and adolescent psychiatric care: An international perspective.

Koelch M, Fegert JM.

Int Rev Psychiatry. 2010;22(3):258-66. doi: 10.3109/09540261.2010.485979. Review.

PMID:
20528655
13.

Newsmaker interview. Francis Collins: on recruiting Varmus, discovering drugs, the funding cliff. Interview by Jocelyn Kaiser.

Collins F.

Science. 2010 May 28;328(5982):1090-1. doi: 10.1126/science.328.5982.1090. No abstract available.

PMID:
20508101
14.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

15.

Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, Decarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):212-20. doi: 10.1016/j.jalz.2010.03.004. Review.

16.

Integrating ADNI results into Alzheimer's disease drug development programs.

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5. Review.

17.

NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.

Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M.

NIH Consens State Sci Statements. 2010 Apr 28;27(4):1-30. Review.

18.

Alzheimer's disease: strategies for disease modification.

Citron M.

Nat Rev Drug Discov. 2010 May;9(5):387-98. doi: 10.1038/nrd2896. Review.

PMID:
20431570
19.

Can open-source drug R&D repower pharmaceutical innovation?

Munos B.

Clin Pharmacol Ther. 2010 May;87(5):534-6. doi: 10.1038/clpt.2010.26. Review.

PMID:
20407458
20.

Mechanism-based approaches to treating fragile X.

Dölen G, Carpenter RL, Ocain TD, Bear MF.

Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18. Review.

PMID:
20303363

Supplemental Content

Support Center